Examples include MYCN upregulation (seen in H3.3-G34R in GBM and potentially impacted by H3.1 imbalance), silencing of tumour suppressors like p16 by H3.3-K27M and activation of oncogenic pathways such as GPR87 by H3.3 in lung cancer. This evidence concerns the gene GPR87 and lung carcinoma.